Keywords
Ambroxol
Inhalation therapy
Neonatal pneumonia
Clinical efficacy
Submitted : 2025-03-06
Accepted : 2025-03-21
Published : 2025-04-05
Abstract
This study explores the clinical efficacy of budesonide combined with ambroxol inhalation therapy for neonatal pneumonia. A total of 68 neonatal pneumonia patients treated at Li County Hospital from January 2023 to December 2024 were randomly divided into a monotherapy group and a combination group, with 34 patients in each. The monotherapy group received ambroxol inhalation therapy, while the combination group received budesonide inhalation therapy in addition to ambroxol. The recovery progress, blood gas analysis indicators, inflammatory response improvement, and overall clinical efficacy were compared between the two groups. Results showed that the combination group experienced a significantly shorter time for body temperature normalization (3.36 ± 0.58 days vs. 4.59 ± 0.45 days), oxygen inhalation duration (4.89 ± 0.57min vs. 6.96 ± 0.79min), disappearance of shortness of breath and cough (4.56 ± 0.29 days vs. 6.63 ± 0.75 days), and resolution of lung wet rales (5.62 ± 1.46 days vs. 7.92 ± 1.28 days) compared to the monotherapy group (P < 0.05). Additionally, the total effective rate was significantly higher in the combination group (97.06%) than in the monotherapy group (73.52%) (P<0.05). Post-treatment, the combination group exhibited significantly better blood gas analysis and inflammatory response indicators (P<0.05). These findings suggest that budesonide combined with ambroxol inhalation therapy can effectively improve blood oxygen saturation, reduce inflammation, promote faster recovery, and enhance overall clinical efficacy, making it a reliable treatment option for neonatal pneumonia.
References
Liu L, Lv J, 2025, Clinical Effect of Ambroxol Combined With Budesonide Nebulization in the Treatment of Neonatal Pneumonia. Women’s and Children’s Health Guide, 4(01): 98–101.
Wang X, 2022, The Effect of Ambroxol Combined With Budesonide Nebulization in the Treatment of Neonatal Pneumonia on Treatment Efficacy and Lung Function. Northern Pharmacology, 19(12): 61–63.
Shao X, Ye H, Qiu X, 2011, Practical Neonatology. People’s Medical Publishing House, 123–126.
Zhou J, Wu G, Xie F, et al., 2022, Study on the Efficacy of Budesonide Suspension Combined With Ambroxol Nebulization in the Treatment of Neonatal Pneumonia and Its Effect on Myocardial Enzymes. Modern Diagnosis and Treatment, 33(16): 2412–2414.
Huo S, Shu G, Wang Y, et al., 2022, The Effect of Ambroxol Combined With Budesonide Suspension Nebulization on Severe Neonatal Pneumonia. Chinese Journal of Clinical Pharmacology, 38(16): 1847–1850.
Liu Q, Li X, Ma J, 2024, The Effect of Nasal High-Flow Humidified Oxygen Therapy Combined With Budesonide and Ambroxol Hydrochloride in the Treatment of Neonatal Pneumonia and Its Influence on TGF-B1 and LPS Levels. Clinical Medical Research and Practice, 9(17): 53–56.
Li B, Zhu L, 2023, The Effect of Intravenous Injection of Ambroxol Hydrochloride Combined With Budesonide Nebulization on Neonatal Pneumonia and Hypersensitive C-Reactive Protein and Procalcitonin. Chinese Journal of Pharmaceutical Economics, 18(10): 80–83.
Zeng Q, Chen J, 2022, The Efficacy of Ambroxol Hydrochloride Combined With Budesonide Suspension Nebulization in the Treatment of Neonatal Pneumonia and Its Effect on Inflammatory Response. Journal of Clinical Rational Drug Use, 15(36): 144–147.
Huang Y, 2024, Clinical Effect of Ambroxol Combined With Budesonide Nebulization in the Treatment of Neonatal Pneumonia. Reflectotherapy and Rehabilitation Medicine, 5(16): 96–98.